Welcome on Hemarina website
Hemarina is a biotechnology company developing a new generation of oxygen-carrier.
The use of Arenicola marina hemoglobin as oxygen-carrying RBC substitute was discovered by Pr. François Lallier, Dr. Franck Zal and Pr. André Toulmond.
|
During the last 70 years, attempts have been made to develop an oxygen-carrier which would help cope with the huge deficit of blood worldwide.
Patients undergoing surgery, transplantation, accident victims, soldiers hurt in theatres of operations, victims of terrorist attacks, victims of natural disasters, etc… all await an efficient alternative to blood transfusion.
Hemarina develops an hemoglobin oxygen-carrier that has shown promising results in pre-clinical trials for further use in Human.
This hemoglobin (HbAm) is extracted and purified from a marine organism and possesses all the characteristics required for an efficient oxygen-carrier red blood cell substitute.
|
|
|
News
"Innovative company" label, awarded by OSEO, the French national agency for innovation
Hemarina SA has obtained the label "Innovative Company", awarded by OSEO Innovation, valid for 3 years, opening access to investments through Innovation mutual Funds (FCPI).
For further information about it, you can contact us or visit Oseo’s website.
|
Monday, july 21th 2008 was the Hemarina’s premises opening day at the “Pépinière d’Entreprises de Morlaix”. Hemarina was proud to have Professor Jean-Marie Lehn, Chemistry Nobel Prize in 1987, to cut the opening ribbon and so being the witness of this event.
Many local, territorial and national authorities were here too to celebrate the expansion of a breton biotechnology company and to prove their real support and belief in the Hemarina's project.
|
The Chief Technical Officer of Hemarina has received a special mention at the "Prix Bretagne Jeune Chercheur 2007", 5th december 2007, at the Tambour Auditorium of Rennes
Morgane Rousselot has been rewarded in the "Terre et Mer : exploitation et préservation" ("Earth and Sea : exploitation and preservation") category, for her work on the therapy for ischemias and anemias.
|
 
The research and development program of Hemarina, called HEMORGAN was labeled by the competitiveness cluster Mer-Bretagne and received a grant by the ANR program “biotechnology research and innovation”
|
Dr. Gilles Avenard Co-Founder and COO of Bioalliance Pharma SA has accepted to be a Board member of HEMARINA |
|
